Evidence map›Paper›PMID 40313650›Full record

ArticleIndian journal of psychological medicine2025

Intravenous Ketamine Treatment for Depression: One-year Retrospective Study from a Tertiary Care Psychiatry Center from India.

Ekta Yadav, Bheemsain Tekkalaki, Kavita P Gadadavar, Vishwas Yadawad, Sameeran S Chate, Sandeep Patil, Vinayak Koparde

Abstract read
In one paragraph

Article in Indian journal of psychological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ekta YadavDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.ORCID https://orcid.org/0009-0004-2772-9237
Bheemsain TekkalakiDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Kavita P GadadavarDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Vishwas YadawadDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.ORCID https://orcid.org/0000-0001-7680-4572
Sameeran S ChateDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Sandeep PatilDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Vinayak KopardeDept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Major depressive disorder (MDD) is a debilitating mental health condition characterized by significant morbidity and mortality. The emergence of ketamine infusion therapy has provided a promising, rapidly acting treatment option. We aimed to assess the effectiveness of ketamine infusion therapy as an adjunct treatment in patients with depression and to study the patient's profile undergoing ketamine therapy in a real-world clinical setting. Methods: This was a retrospective chart review. A total of 28 patients with depression who received ketamine infusion therapy at a tertiary care hospital were included in this retrospective analysis. The Hamilton Depression Rating Scale (HAMD) was utilized to assess depressive symptomatology. Results: A statistically significant reduction in HAMD scores was observed post-treatment ( Conclusion: The finding of this study indicates that ketamine infusion therapy is safe and effective as a rapidly acting adjunct treatment for depression.

Indexed as

depressionKetamine infusion therapysuicidal ideationtreatment-resistant depression

Identifiers

PMID40313650
PMCPMC12040862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.